A Phase 4 interventional study of Rituximab in Rheumatoid Arthritis, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 36th largest by planned enrollment, is the only one that started in 2024, is one of 14 in phase 4, and was the 59th registered.
3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 134 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this open label multicenter randomized controlled pragmatic superiority trial is to investigate the optimal treatment/tapering strategy with rituximab for patients with rheumatoid arthritis.
The main questions it aims to answer are:
Participants will be randomized to one of two study arms:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP. DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum). DAS28-CRP \> 3.2: administration of previously effective dose.
Drug: Rituximab
Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.
Drug: Rituximab
IV rituximab
Also known as: MabThera, Truxima, Ruxience, Rixathon
Comparison of disease impact in both study arms, measured using the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire
RAID questionnaire score range: 0 - 10, with higher scores indicating worse status.
Time frame: Over 2 years (104 weeks)
Comparison of disease activity in both study arms, measured using the Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP)
Main secondary outcome. DAS28-CRP range: 0 - ..., with higher values indicating higher disease activity.
Time frame: Over 2 years (104 weeks)
Comparison of disease activity in both study arms, measured using the Simplified Disease Activity Index (SDAI)
SDAI range: 0 - ..., with higher values indicating higher disease activity.
Time frame: Over 2 years (104 weeks)
Comparison of cumulative dose of rituximab in both study arms
Time frame: Over 2 years (104 weeks)
Comparison of cumulative dose of glucocorticoids in both study arms
Time frame: Over 2 years (104 weeks)
Proportion of patients in both study arms achieving a good or moderate European League Against Rheumatism (EULAR) treatment response after administration of rituximab, over a period of 2 years (104 weeks)
A good EULAR response is defined as a decrease in Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) \> 1.2 and a present DAS-CRP ≤ 3.2. A moderate EULAR response is defined as a decrease in DAS28-CRP \> 0.6 to ≤ 1.2 and a present DAS28-CRP ≤ 5.1, or a decrease in DAS28-CRP \> 1.2 and a present DAS28-CRP \> 3.2. Treatment responses will be evaluated 12 weeks after every administration of rituximab.
Time frame: Over 2 years (104 weeks)
Comparison of loss of disease control in both study arms
Loss of disease control is defined as achieving a Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) \> 3.2 with previous DAS28-CRP ≤ 3.2.
Time frame: Over 2 years (104 weeks)
Comparison of rituximab drug retention rate in both study arms
Defined as the percentage of patients remaining on treatment with rituximab over time.
Time frame: Over 2 years (104 weeks)
Proportion of patients tapering rituximab below 1000 mg in the experimental arm
Time frame: Over 2 years (104 weeks)
Mean/median interval between rituximab administrations in the active comparator group
Time frame: Over 2 years (104 weeks)
Comparison of serious adverse events/reactions rates in both study arms.
An adverse event or adverse reaction is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.
Time frame: Over 2 years (104 weeks)
Comparison of serious infections rate in both study arms.
An infection is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.
Time frame: Over 2 years (104 weeks)
Comparison of functional status in both study arms, measured using the Health Assessment Questionnaire - Disability Index (HAQ-DI)
HAQ-DI score range: 0 - 3, with higher scores indicating worse functional status.
Time frame: Over 2 years (104 weeks)
Self-efficacy in both study arms, measured using the Arthritis Self-Efficacy Scale (ASES)
ASES score range: 11 - 110, with higher scores indicating higher perceived self-efficacy.
Time frame: Over 2 years (104 weeks)
Pain in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
VAS pain range: 0 - 100, with higher values indicating higher pain
Time frame: Over 2 years (104 weeks)
Fatigue in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
VAS fatigue range: 0 - 100, with higher values indicating more fatigue.
Time frame: Over 2 years (104 weeks)
Patient global assessment (PGA) of disease in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
VAS PGA range: 0 - 100, with higher values indicating worse disease.
Time frame: Over 2 years (104 weeks)
Cluster of Differentiation (CD) 19+ and Memory B cell counts in both study arms
Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.
Time frame: Over 2 years (104 weeks)
Immunoglobulin (Ig) counts (IgG, IgA and IgM) in both study arms
Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.
Time frame: Over 2 years (104 weeks)
Professional and vocational participation in both study arms, calculated using the Work Productivity and Activity Impairment questionnaire: General Health (WPAI:GH)
The WPAI:GH calculates the percent work time missed due to health (range 0-100, higher numbers indicating more missed work time), the percent impairment while working due to health (range 0-100, higher numbers indicating higher impairment), the percent overall work impairment due to health (range 0-100, higher numbers indicating higher impairment), and the percent activity impairment due to health (range 0-100, higher numbers indicating higher impairment).
Time frame: Over 2 years (104 weeks)
Health utility index in both study arms, calculated using the summary index score of the EuroQol - 5 dimensions (EQ-5D) questionnaire
Summary index score range: less than 0 (health state worse than dead, 0 being the value of a health state equivalent to death) to 1 (full health).
Time frame: Over 2 years (104 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.
Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 47 months is close to that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Universitaire Ziekenhuizen KU Leuven →